Stock Events

Stock Events

Allergy Therapeutics 

$0.150000
8
+$0.01+7.14% Thursday 13:30

Statistics

Day High
0.15
Day Low
0.15
52W High
0.15
52W Low
0.085
Volume
7,142
Avg. Volume
508
Mkt Cap
714.97M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

24SepExpected
Q1 2024
Q3 2024
Q4 2024
Q2 2025
Q3 2025
Q4 2025
Next
-0.53
-0.43
-0.33
-0.22
Expected EPS
-0.4707613728
Actual EPS
N/A

Financials

-75.24%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
71.45MRevenue
-53.76MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AGYTF. It's not an investment recommendation.
Rolls-Royce
3
RR.LSE
Tesco
3
TSCO.LSE
Legal & General Group
2
LGEN.LSE
BP
2
BP.LSE

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alaska Air Group
ALK
Mkt Cap4.72B
ALK-Abelló is a leading company in the field of allergy immunotherapy, directly competing with Allergy Therapeutics in developing treatments for allergic conditions.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals, through its development of Dupixent for various allergic conditions, competes in the allergy treatment market, impacting companies like Allergy Therapeutics.
Sanofi
SNY
Mkt Cap107.39B
Sanofi, in partnership with Regeneron, markets Dupixent, a direct competitor in the allergy treatment space, affecting Allergy Therapeutics' market share.
Novavax
NVAX
Mkt Cap1.53B
Novavax is involved in the development of vaccines that could prevent allergic reactions, indirectly competing with Allergy Therapeutics' approach to allergy management.
Merck
MRK
Mkt Cap366B
Merck & Co., with its range of allergy and asthma treatments, competes in the broader market for allergic condition management, impacting Allergy Therapeutics.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca offers several products for respiratory and allergic conditions, competing in the same therapeutic area as Allergy Therapeutics.
GSK
GSK
Mkt Cap101.78B
GlaxoSmithKline produces a variety of medications for asthma and allergic rhinitis, competing with Allergy Therapeutics in the respiratory and allergy medication market.

About

Allergy Therapeutics plc is a biotechnology firm dedicated to the research, development, and commercialization of innovative treatments for allergic conditions. The company offers a variety of allergen-specific immunotherapies, available as both injectable solutions and sublingual (under-the-tongue) formulations. Their product line includes prescription medications specifically designed to address pollen-related allergies, such as those caused by grasses, weeds, and trees, along with various diagnostic tools. Key products in their portfolio feature names like Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Pollinex, VLP Peanut, and Penicillin diagnostics. Furthermore, Allergy Therapeutics is actively developing new allergy vaccines targeting a range of allergens, including trees, grass, house dust mites, animal dander, and peanuts. The company operates extensively across Central Europe, Southern Europe, the United Kingdom, and extends its market presence internationally. Established in 2004, Allergy Therapeutics plc is based in Worthing, United Kingdom.
Show more...
CEO
Manuel Llobet
Employees
612
Country
United Kingdom
ISIN
GB00B02LCQ05
WKN
000A0EAWN

Listings

STU
DE
HHU.STU
F
DE
HHU.F
MU
DE
HHU.MU
LSE
GB
AGY.LSE

0 Comments

Share your thoughts

FAQ

What is Allergy Therapeutics stock price today?▼
The current price of AGYTF is $0.15 USD — it has increased by +7.14% in the past 24 hours. Watch Allergy Therapeutics stock price performance more closely on the chart.
What is Allergy Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Allergy Therapeutics stocks are traded under the ticker AGYTF.
Is Allergy Therapeutics stock price growing?▼
AGYTF stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Allergy Therapeutics has showed a +76.47% increase.
What is Allergy Therapeutics market cap?▼
Today Allergy Therapeutics has the market capitalization of 714.97M
When is the next Allergy Therapeutics earnings date?▼
Allergy Therapeutics is going to release the next earnings report on September 24, 2026.
What were Allergy Therapeutics earnings last quarter?▼
AGYTF earnings for the last quarter are -0.01 USD per share, whereas the estimation was -0.01 USD resulting in a +0% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Allergy Therapeutics revenue for the last year?▼
Allergy Therapeutics revenue for the last year amounts to 71.45M USD.
What is Allergy Therapeutics net income for the last year?▼
AGYTF net income for the last year is -53.76M USD.
How many employees does Allergy Therapeutics have?▼
As of September 06, 2026, the company has 612 employees.
In which sector is Allergy Therapeutics located?▼
Allergy Therapeutics operates in the Health & Wellness sector.
When did Allergy Therapeutics complete a stock split?▼
Allergy Therapeutics has not had any recent stock splits.
Where is Allergy Therapeutics headquartered?▼
Allergy Therapeutics is headquartered in Worthing, United Kingdom.